Genetic manipulation of NK cells for cancer immunotherapy: Techniques and clinical implications

Frontiers in Immunology

Volumn 6, Issue JUN, 2015, Pages

  Carlsten, Mattias ^a   Childs, Richard W ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cancer immunotherapy; Electroporation; Genetic manipulation; NK cells; Viral transduction

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 2; LENTIVIRUS VECTOR; NATURAL KILLER CELL RECEPTOR; RETROVIRUS VECTOR;

CANCER IMMUNOTHERAPY; CELL MIGRATION; CELL THERAPY; CELL VIABILITY; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; ELECTROPORATION; GENE TRANSFER; GENETIC ENGINEERING; GENETIC MANIPULATION; GENETIC TRANSFECTION; HUMAN; NATURAL KILLER CELL; NUCLEOFECTION; REVIEW; T LYMPHOCYTE; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

EID: 84935039266     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00266     Document Type: Review

References (74)

1. Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, et al. The trafficking of natural killer cells. Immunol Rev (2007) 220:169-82. doi: 10.1111/j.1600-065X.2007.00563.x
2. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer (1975) 16:230-9. doi:10.1002/ijc.2910160204
3. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer (1975) 16:216-29. doi:10.1002/ijc.2910160204
4. Kiessling R, Klein E, Pross H, Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol (1975) 5:117-21. doi:10.1002/eji.1830050208
5. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol (1975) 5:112-7. doi:10.1002/eji.1830050208
6. Miller JS, Soignier Y, Panoskaltsis-Mortari A, Mcnearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 105:3051-7. doi:10.1182/blood-2004-07-2974
7. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, et al. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol (2012) 189:5082-8. doi:10.4049/jimmunol.1201964
8. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood (2012) 119:2665-74. doi:10.1182/blood-2011-10-386995
9. Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood (2009) 114:2657-66. doi:10.1182/blood-2009-01-201632
10. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 295:2097-100. doi:10.1126/science.1068440
11. Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood (2011) 118:1402-12. doi:10.1182/blood-2010-08-304121
12. Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, Mckenna DH, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood (2014) 123:3855-63. doi:10.1182/blood-2013-10-532531
13. Ito S, Bollard CM, Carlsten M, Melenhorst JJ, Biancotto A, Wang E, et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther (2014) 22:1388-95. doi:10.1038/mt.2014.50
14. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med (2014) 65:333-47. doi:10.1146/annurev-med-060512-150254
15. Sutlu T, Nystrom S, Gilljam M, Stellan B, Applequist SE, Alici E. Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Hum Gene Ther (2012) 23:1090-100. doi:10.1089/hum.2012.080
16. Nagashima S, Mailliard R, Kashii Y, Reichert TE, Herberman RB, Robbins P, et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood (1998) 91:3850-61.
17. Yusa S, Catina TL, Campbell KS. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells. J Immunol (2002) 168:5047-57. doi:10.4049/jimmunol.168.10.5047
18. Becknell B, Trotta R, Yu J, Ding W, Mao HC, Hughes T, et al. Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector. J Immunol Methods (2005) 296:115-23. doi:10.1016/j.jim.2004.11.012
19. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol (2008) 180:6392-401. doi:10.4049/jimmunol.180.9.6392
20. Guven H, Konstantinidis KV, Alici E, Aints A, Abedi-Valugerdi M, Christensson B, et al. Efficient gene transfer into primary human natural killer cells by retroviral transduction. Exp Hematol (2005) 33:1320-8. doi:10.1016/j.exphem.2005.07.006
21. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 106:376-83. doi:10.1182/blood-2004-12-4797
22. Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A (2008) 105:17481-6. doi:10.1073/pnas.0804788105
23. Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res (2009) 15:4857-66. doi:10.1158/1078-0432.CCR-08-2810
24. Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res (2013) 73:1777-86. doi:10.1158/0008-5472.CAN-12-3558
25. Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SM, Coustan-Smith E, et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood (2014) 124:1081-8. doi:10.1182/blood-2014-02-556837
26. Micucci F, Zingoni A, Piccoli M, Frati L, Santoni A, Galandrini R. High-efficient lentiviral vector-mediated gene transfer into primary human NK cells. Exp Hematol (2006) 34:1344-52. doi:10.1016/j.exphem.2006.06.001
27. Savan R, Chan T, Young HA. Lentiviral gene transduction in human and mouse NK cell lines. Methods Mol Biol (2010) 612:209-21. doi:10.1007/978-1-60761-362-6_14
28. Boissel L, Betancur M, Lu W, Wels WS, Marino T, Van Etten RA, et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma (2012) 53:958-65. doi:10.3109/10428194.2011.634048
29. Sahm C, Schonfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother (2012) 61:1451-61. doi:10.1007/s00262-012-1212-x
30. Baeriswyl V, Wodnar-Filipowicz A, Kalberer CP. The effect of silencing NKG2D through RNA interference on receptor functions in interleukin-2-activated human natural killer cells. Haematologica (2006) 91:1538-41.
31. Figueiredo C, Seltsam A, Blasczyk R. Permanent silencing of NKG2A expression for cell-based therapeutics. J Mol Med (Berl) (2009) 87:199-210. doi:10.1007/s00109-008-0417-0
32. Maasho K, Marusina A, Reynolds NM, Coligan JE, Borrego F. Efficient gene transfer into the human natural killer cell line, NKL, using the amaxa nucleofection system. J Immunol Methods (2004) 284:133-40. doi:10.1016/j.jim.2003.10.010
33. Schoenberg K, Trompeter HI, Uhrberg M. Delivery of DNA into natural killer cells for immunotherapy. Methods Mol Biol (2008) 423:165-72. doi:10.1007/978-1-59745-194-9_11
34. Yang B, Liu H, Shi W, Wang Z, Sun S, Zhang G, et al. Blocking transforming growth factor-beta signaling pathway augments antitumor effect of adoptive NK-92 cell therapy. Int Immunopharmacol (2013) 17:198-204. doi:10.1016/j.intimp.2013.06.003
35. Liu H, Yang B, Sun T, Lin L, Hu Y, Deng M, et al. Specific growth inhibition of ErbB2expressing human breast cancer cells by genetically modified NK92 cells. Oncol Rep (2015) 33:95-102. doi:10.3892/or.2014.3548
36. Schirrmann T, Pecher G. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Ther (2002) 9:390-8. doi:10.1038/sj.cgt.7700453
37. Grund EM, Muise-Helmericks RC. Cost efficient and effective gene transfer into the human natural killer cell line, NK92. J Immunol Methods (2005) 296:31-6. doi:10.1016/j.jim.2004.10.008
38. Schirrmann T, Pecher G. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res (2005) 29:301-6. doi:10.1016/j.leukres.2004.07.005
39. Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res (2009) 33:1255-9. doi:10.1016/j.leukres.2008.11.024
40. Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther (2010) 17:147-54. doi:10.1038/cgt.2009.61
41. Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy (2012) 14:830-40. doi:10.3109/14653249.2012.671519
42. Tran J, Kung SK. Lentiviral vectors mediate stable and efficient gene delivery into primary murine natural killer cells. Mol Ther (2007) 15:1331-9. doi:10.1038/sj.mt.6300184
43. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet (2003) 4:346-58. doi:10.1038/nrg1066
44. Biasco L, Baricordi C, Aiuti A. Retroviral integrations in gene therapy trials. Mol Ther (2012) 20:709-16. doi:10.1038/mt.2011.289
45. Zhang J, Sun R, Wei H, Zhang J, Tian Z. Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy. Oncol Rep (2004) 11:1097-106. doi:10.3892/or.11.5.1097
46. Liu JH, Wei S, Blanchard DK, Djeu JY. Restoration of lytic function in a human natural killer cell line by gene transfection. Cell Immunol (1994) 156:24-35. doi:10.1006/cimm.1994.1150
47. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, Metz S, et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol (2005) 15:4-13. doi:10.1007/s00330-004-2526-7
48. Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol (2014) 8:297-310. doi:10.1016/j.molonc.2013.12.001
49. Jiang W, Zhang J, Tian Z. Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL. Cytotherapy (2008) 10:265-74. doi:10.1080/14653240801965156
50. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol (2014) 32:347-55. doi:10.1038/nbt.2842
51. Konstantinidis KV, Alici E, Aints A, Christensson B, Ljunggren HG, Dilber MS. Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells. Exp Hematol (2005) 33:159-64. doi:10.1016/j.exphem.2004.11.003
52. Jiang W, Zhang C, Tian Z, Zhang J. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo. Immunobiology (2014) 219:547-53. doi:10.1016/j.imbio.2014.03.007
53. Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, et al. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology (2013) 2:e26527. doi:10.4161/onci.26527
54. Muller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother (2008) 57:411-23. doi:10.1007/s00262-007-0383-3
55. Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia (2014) 28:917-27. doi:10.1038/leu.2013.279
56. Esser R, Muller T, Stefes D, Kloess S, Seidel D, Gillies SD, et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med (2012) 16:569-81. doi:10.1111/j.1582-4934.2011.01343.x
57. Lee JM, Yoon SH, Kim HS, Kim SY, Sohn HJ, Oh ST, et al. Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model. Cancer Gene Ther (2010) 17:742-50. doi:10.1038/cgt.2010.30
58. Kobayashi E, Kishi H, Ozawa T, Hamana H, Nakagawa H, Jin A, et al. A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells. Biochem Biophys Res Commun (2014) 453:798-803. doi:10.1016/j.bbrc.2014.10.024
59. Zhang G, Liu R, Zhu X, Wang L, Ma J, Han H, et al. Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunol Cell Biol (2013) 91:615-24. doi:10.1038/icb.2013.45
60. Childs RW, Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. Hematology Am Soc Hematol Educ Program (2013) 2013:234-46. doi:10.1182/asheducation-2013.1.234
61. Miller JS, Rooney CM, Curtsinger J, Mcelmurry R, Mccullar V, Verneris MR, et al. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant (2014) 20:1252-7. doi:10.1016/j.bbmt.2014.05.004
62. Somanchi SS, Somanchi A, Cooper LJ, Lee DA. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood (2012) 119:5164-72. doi:10.1182/blood-2011-11-389924
63. Wennerberg E, Kremer V, Childs R, Lundqvist A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol Immunother (2015) 64:225-35. doi:10.1007/s00262-014-1629-5
64. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 257:107-26. doi:10.1111/imr.12131
65. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 99:754-8. doi:10.1182/blood.V99.3.754
66. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 21:3940-7. doi:10.1200/JCO.2003.05.013
67. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest (1997) 100:1059-70. doi:10.1172/JCI119616
68. Carlsten M, Li L, Su S, Berg M, Reger R, Madhusudan P, et al. Clinical-grade mRNA electroporation of NK cells: a novel and highly efficient method to genetically reprogram human NK cells for cancer immunotherapy. ASH Annual Meeting Abstracts: San Francisco (2014).
69. Tijsterman M, Ketting RF, Plasterk RH. The genetics of RNA silencing. Annu Rev Genet (2002) 36:489-519. doi:10.1146/annurev.genet.36.043002.091619
70. Furutani E, Su S, Smith A, Berg M, Childs R. siRNA inactivation of the inhibitory receptor NKG2A augments the anti-tumor effects of adoptively transferred NK cells in tumor-bearing hosts. ASH Annual Meeting Abstracts: Orlando (2010).
71. Purdy AK, Campbell KS. Introduction of shRNAs into human NK-like cell lines with retrovirus. Methods Mol Biol (2010) 612:223-31. doi:10.1007/978-1-60761-362-6_15
72. Karasuyama H, Tohyama N, Tada T. Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene. J Exp Med (1989) 169:13-25. doi:10.1084/jem.169.1.13
73. Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol (2014) 5:254. doi:10.3389/fphar.2014.00254
74. Klingemann HG, Wong E, Maki G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant (1996) 2:68-75.